Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis
Open Access
- 9 April 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (7), 1383-1387
- https://doi.org/10.1182/bloodadvances.2020001497
Abstract
First evidence of ruxolitinib efficacy for subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic lymphohistiocytosis. Supporting rationale for ruxolitinib use, not more aggressive treatment, in this context, questioning this condition’s neoplastic nature.This publication has 20 references indexed in Scilit:
- Subcutaneous Panniculitis-like T-cell Lymphoma: Immunosuppressive Drugs Induce Better Response than PolychemotherapyActa Dermato-Venereologica, 2017
- Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in miceBlood, 2016
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune RegulationImmunity, 2016
- Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosisBlood, 2016
- Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosisFuture Oncology, 2015
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia VeraThe New England Journal of Medicine, 2015
- Subcutaneous panniculitis‐like T‐cell lymphoma in the pediatric age group: A lymphoma of low malignant potentialPediatric Blood & Cancer, 2013
- Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 casesBlood, 2008
- Increased serum levels of interferon-γ-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosisClinical and Experimental Immunology, 2003